SYNTAGMA CAPITAL Completes the Acquisition of Aginode, the LAN/Data Center (“LAN/DC”) and Telecom/Fibre (“FTTx”) Division of Nexans SA (Euronext Paris: NEX)

BRUSSELS - Thursday, 02. November 2023

(BUSINESS WIRE) -- Syntagma Capital today announces that it has completed its acquisition of Aginode (https://www.aginode.net), formerly known as Nexans Telecom & Data.

The company, rebranded a few months ago to Aginode, designs, manufactures, and distributes smart connectivity solutions based on optical fibre and copper technologies to data centers, smart buildings, and telecom operators. In 2022, the business generated ca. €200m in revenues across 100+ countries thanks to its 8 industrial sites in France, Belgium, Germany, Greece, Morocco and China. The business employs ca. 680 employees worldwide.

“Syntagma is pleased to announce today the completion of the Aginode transaction, the second portfolio company of the fund. The M&A market remains challenging and this achievement demonstrates our ability to navigate through uncertain times and continue to provide divestiture solutions that deliver speed and certainty while being highly selective on our capital allocation,” said Syntagma Managing Partner Sebastien Kiekert Le Moult.

“We are thrilled by Aginode’s potential and look forward to teaming up with the management to steer the company towards a future of unprecedented success,” said Syntagma Partner Frank Coenen.

Syntagma’s team involved in the transaction included Sebastien Kiekert Le Moult (Managing Partner), Frank Coenen (Partner), Benjamin Dahan (Partner), João Pilecco (Senior Vice President), Ludovic Ruffenach (Senior Associate), and Alicia Azéma (Senior Analyst).

Syntagma was advised by Willkie Farr Gallagher (Hugo Nocerino, Ji-Soo Kim, Rudy Merlet, Faustine Viala, Charles Bodreau, Charles-Antoine Erignac, Jordan Pontal), PwC Transaction (Eric Douheret, Clément Meudec, François-Xavier Bornet, Edouard Bitton), PwC Tax and Legal (Anne-Valerie Attias-Assouline, Mathieu Norest, Morgane Croisier, Aurélie Cluzel-d’Andlau, Claire Pascal Oury), Roland Berger (Victor Marcais, Yaroslav Stetsenko) and ERM (Maryelle Ouvrard, ChinChin Lim).

About Syntagma Capital
Syntagma invests in companies that can benefit from hands-on operational expertise to accelerate growth and improve performance for all stakeholders. We are true operators with experience working in and managing companies on a global scale, leveraging our in-house resources to develop successful strategies, execute them to realize their full potential and create sustainable long-term value. Syntagma invests and operates companies in a broad range of industries with a specific focus on the material, chemical, industrial and business services markets and including manufacturing, distribution, transportation and logistics, equipment rental, metals services and other industries. Syntagma, as signatory of the UN PRI, is committed to high ESG standards across all its investments and is based in Brussels, Belgium. For more information, please visit: https://syntagmacapital.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102247270/en/

Permalink
https://www.aetoswire.com/en/news/0211202335580

Contacts

Marie Ciparisse
+32 (0)2 315 70 12
mciparisse@syntagmacapital.com

MSCI Completes Acquisition of Trove Research

 NEW YORK - Thursday, 02. November 2023 AETOSWire Print 

(BUSINESS WIRE) -- MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that it has completed its acquisition of Trove Research, a firm specializing in data and analytics on the voluntary carbon markets.

The acquisition was originally announced on October 10, 2023.

Henry Fernandez, Chairman and Chief Executive Officer, MSCI, said: “The completion of this acquisition represents a milestone for MSCI. Trove’s data and analytics will help us develop a wide range of solutions for the voluntary carbon market, which is critical to supporting our clients as they manage carbon emissions in their portfolios. Through these solutions, MSCI will promote greater clarity and consistency for investors and companies across industries.”

About MSCI Inc.

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com. MSCI#IR

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements relating to the integration of Trove Research and prospects for the newly acquired business. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.

Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 10, 2023 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231101965032/en/

Permalink

https://www.aetoswire.com/en/news/0211202335565

Contacts

Investor Inquiries

jeremy.ulan@msci.com

Jeremy Ulan +1 646 778 4184

jisoo.suh@msci.com

Jisoo Suh +1 917 825 7111

Media Inquiries

PR@msci.com

Melanie Blanco +1 212 981 1049

Konstantinos Makrygiannis +44 (0) 7768 930056

Tina Tan +852 2844 9320

MSCI Global Client Services

EMEA Client Service + 44 20 7618.2222

Americas Client Service +1 888 588 4567 (toll free)

Asia Pacific Client Service + 852 2844 9333

Cognite Releases Industry's First Definitive Guide to Generative AI

 "The Definitive Guide to Generative AI for Industry," is a comprehensive manual for transformation leaders to accelerate AI innovation and reduce time to value of their digital transformation programs

(BUSINESS WIRE) -- Cognite, a globally recognized leader in industrial software, today announced the release of "The Definitive Guide To Generative AI for Industry", a manual for companies to accelerate AI innovation and reduce time to value.

"The Definitive Guide to Generative AI for Industry," explains and defines the technological requirements necessary to make AI work for industry. The book offers practical advice on successful AI adoption and scaling—including specific use case examples—and provides tools for digital leaders to scope and plan their digital journey and define and measure success in terms the enterprise will understand. Generative AI is the most transformative technology to hit the market in ten years, and industrial organizations across the Energy and Manufacturing sectors are scrambling to keep pace with the accelerating, data-driven shifts that modern organizations must now navigate.

"The ability to converse with a machine presents far more than just entertainment value. Machines capable of translating natural language into machine language, while preserving intent – and context – provide the non-coder with code-level access. Plus, human language has been evolving for millennia and is now well-suited to general-purpose applications,” said Joe Lamming, Industry Analyst, Verdantix. "Cognite's work so far with Large Language Models ( LLMs), grounded by its Industrial DataOps platform, is remarkable – with even greater value on the horizon in the form of not just data management, but information orchestrated by real, thoughtful AI."

"Generative AI is fundamentally reshaping operational processes and it will be the digital mavericks who will be early adopters of this technology. Celanese has set the standard in industrial innovation with its Digital Plant of the Future; and by working with Cognite to accelerate AI implementation into our digital transformation strategy, it will allow us to raise the stakes once again and solidify Celanese as a leader in advanced manufacturing," said Brenda Stout – Vice President Manufacturing, Celanese

"Safe, secure, hallucination-free generative AI is critical to paving the road to sustainable and profitable global energy supply and manufacturing excellence. However, industrial organizations can only leverage generative AI successfully by solving the industrial data problem first," said Girish Rishi, CEO at Cognite. "This is the moment Cognite was built for, and The Definitive Guide to Generative AI for Industry provides a comprehensive how-to for transformation leaders looking to drive actual bottom-line impact.”

The Definitive Guide to Generative AI for Industry is the second book from Cognite and follows the 2021 release of The Definitive Guide to Industrial DataOps. Together, the books demystify industrial digitalization and help make sense of how Industrial DataOps and Industrial AI can revolutionize how organizations manage complex data. The books reflect the necessary journey industrial companies must take to evaluate, adopt, and scale digital transformations across their organizations.

Physical copies of the book are available for purchase. The full digital version of the book is also available online for free. Visit Cognite to learn more.

About Cognite

Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102460605/en/

Permalink

https://www.aetoswire.com/en/news/0211202335589

Contacts

Michelle Holford

Vice President, Global PR, Cognite

Michelle.holford@cognite.com

 

Quectel Achieves ISO 26262 ASIL B Automotive Functional Safety Certifications as Well as ISO/SAE 21434 Automotive Cybersecurity Management System Certification

 (BUSINESS WIRE) -- Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce it has been awarded the ISO 26262:2018 Functional Safety Process Certificate by Bureau Veritas (BV), a trusted and industry-recognized third-party certification body. This milestone confirms that Quectel has successfully established a complete set of robust functional safety management process system in accordance with ISO 26262 standards, providing continuous support for the design and manufacturing of products that adhere to international safety standards.

In addition, Quectel's LG69T (AB) automotive-grade GNSS module has received certification for meeting the stringent requirements of ISO 26262 ASIL B metrics, which underscores the LG69T (AB)'s ability to fulfill functional safety requirements, positioning it as a dependable solution for global automotive manufacturers and Tier-one suppliers.

Norbert Muhrer, President and CSO, Quectel Wireless Solutions, commented, "Securing ISO 26262 certifications marks a significant milestone in Quectel's commitment to delivering top-tier products and services to the global automotive market. With these certifications, our LG69T (AB) module, and forthcoming products, will play a pivotal role in advancing vehicle safety and the evolution of autonomous driving. Moving forward, we remain dedicated to creating more automotive-grade products that meet safety standards, contributing to the ongoing development of the intelligent driving industry."

As driving technology progresses to more advanced levels of automation, the number of electronic and electrical systems within vehicles continues to grow. The complexity of software and hardware systems presents additional challenges in functional safety technologies. Selecting components compliant with functional safety standards can assist automotive manufacturers and Tier-one suppliers in improving their product development processes, ultimately ensuring vehicle safety.

Quectel’s LG69T (AB) is an automotive-grade high-precision GNSS positioning module based on the STMicroelectronics Teseo APP platform. When combined with multiple positioning technologies such as Real-Time Kinematic (RTK) and Dead Reckoning (DR), this dual-frequency module can achieve centimeter-level positioning accuracy, nanosecond-level real-time response, and time and position sharing between vehicles.

Moreover, the LG69T (AB) features over 40 safety mechanisms encompassing temperature detection, tracking channel checks, signal quality monitoring, voltage monitoring, antenna monitoring, and more, ensuring continuous monitoring of the module's health status. Additionally, its high flexibility and configurability allow customization to meet the functional safety requirements of a wide range of application scenarios, according to customer needs.

In addition to obtaining ISO 26262 functional safety process certification, Quectel has earned other crucial certifications, including ISO/SAE 21434 Automotive Cybersecurity Management System certification which indicates the company’s organizational and engineering processes for cybersecurity are compliant with international standards, as well as ISO 27001 Product Information Security Management System certification, ASPICE CL2, CMMI Level 3, and IATF 16949:2016 Automotive Quality Management System certification. These certifications underscore Quectel's focus in providing high-quality, secure, and compliant automotive products and solutions to global partners in the automotive industry.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102951870/en/

Permalink

https://www.aetoswire.com/en/news/0211202335584

Contacts

Media: media@quectel.com

 

46th ICA Conference & Exhibition in Marrakesh from November 16th to 19th: Official Program Revealed

Casablanca, Morocco, Beirut, Lebanon - Thursday, 02. November 2023

The Moroccan Trading Rooms Association (AMSM) has unveiled the official program for the 46th edition of the Interarab Cambist Association (ICA) Conference & Exhibition. This highly anticipated event is scheduled to take place from November 16th to 19th, 2023, in the enchanting city of Marrakesh, Morocco, at the Four Seasons Hotel.

The conference is themed "How to overcome market challenges and build a stronger tech-driven sustainable future economy." It will bring together leaders and world-class speakers who will share their expertise and perspectives on the global economy and the financial markets industry.

The ICA Conference will bring together 500 global financial market professionals, including experts in capital markets, asset managers, investment bankers, risk management specialists, chief economists, chief strategists, as well as geopolitical experts. This will provide a unique platform for interactive exchanges.

The official conference program is now accessible on the website www.icamorocco2023.com, featuring an impressive lineup of 25 confirmed speakers. Among them, you will find prominent figures such as Mrs. Nadia Fettah, Morocco's Minister of Economy and Finance; Mr. Dominique Strauss-Kahn, the former Managing Director of the IMF; Mr. Miguel Azevedo, Citi's Chairman for Africa and the Middle East; Mrs. Nadia Fassi Fehri, OCP's Group Chief Transformation Officer; Mr. Michael Faye, Chief Executive Officer of Tap-Tap Send; Mr. Alexandre Kateb, a best-selling author and esteemed economist; Mr. Naoufal Alami, who serves as the Global Head of Commodities and Energy Transition Trading at First Abu Dhabi Bank, and Mr. Farid Masmoudi representing the Private Equity firm Ardian.

Participants can still register, explore the comprehensive agenda, and access all relevant information through the website.

About ICA - The Interarab Cambist Association is a nonprofit professional association founded in Beirut, Lebanon, in 1972 following an agreement between foreign exchange dealers in 14 Arab countries. Its members are engaged in financial trading and sales, representing FX, interest rate products, equities, commodities, and more.

About AMSM - AMSM, the Moroccan Trading Rooms Association, plays a pivotal role in advancing capital market activities within Morocco. With a keen focus on enhancing market efficiency, transparency, and international outreach, AMSM brings together market participants to promote shared expertise, align common strategies, and advocate for the Moroccan market on a global stage.

Permalink

https://www.aetoswire.com/en/news/2112023355966

Contacts

Mrs Malika Benjelloun

Hikma continues strong momentum across the Group and upgrades guidance for 2023

 

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses. Our Branded business is performing exceptionally well on an underlying basis and our Generics business has seen key products continuing to drive better-than-expected performance.  In Injectables, we are seeing solid growth, supported by a good performance in MENA and Europe, and we have continued to invest across all our regions to expand manufacturing capacity and build our pipeline. Overall, the Group is making excellent progress and we are on track to deliver very strong earnings growth for the full year.”

Injectables

We continue to see solid growth in our global Injectables business. In North America, while we have continued to see strong customer demand for our broad product portfolio and a good contribution from new product launches in the second half, growth has been lower than expected due to short-term supply and capacity constraints. These constraints are easing as newly installed high-speed manufacturing lines in both our Cherry Hill and Portugal facilities are becoming fully operational and we are well-positioned to meet demand in 2024.

Our MENA business is performing very well, with launches driving growth and offsetting the loss of sales in Sudan.  In Europe, we are delivering strong growth in Germany and Italy and are gradually building share in Spain, France, and the UK.

We are continuing to invest extensively across our Injectables business to expand our portfolio and manufacturing capacity. We are making good progress on our new facilities in Morocco and Algeria and are gradually advancing our 503B sterile compounding business in the US. 

We now expect full year revenue growth and core operating margin to be at the lower end of our guidance range of 7% to 9% and 36% to 37%, respectively.  This takes into consideration the closure of our Sudanese manufacturing facility, investment in our compounding business and the short-term capacity constraints in the US.

Branded

Our Branded business continues to see strong demand. Medicines used to treat chronic illnesses are driving growth across our key MENA markets, offsetting the combined headwinds of the devaluation of the Egyptian Pound and the closure of our Sudanese manufacturing facility.  Leveraging our local manufacturing presence and strong commercial teams, we continue to launch new products, including first-to-market generics and innovative in-licenced products.  Our teams are focused on driving efficiencies at our facilities across the region, and this, combined with a favourable product mix, is leading to improved profitability. 

We continue to expect Branded revenue to grow in the mid-to-high single digits in constant currency. On a reported basis, assuming no further adverse currency movements, we continue to expect Branded revenue to be in line with 2022, offsetting headwinds resulting from the devaluation of the Egyptian Pound and the closure of our Sudan operations. Due to our strong performance and focus on efficiencies, we now expect core operating margin to expand to around 23% for the full year.

Generics

Our Generics business continues to have an excellent year, as we benefit from favourable market dynamics across our base business and a stronger than expected revenue contribution from our authorised generic of sodium oxybate.

We are pleased with the efforts we are making to utilise spare capacity at our Columbus plant for contract manufacturing and are making good progress with our specialty products.

We now expect 2023 revenue in the range of $920 million to $940 million and core operating margin of around 20%, up from previous guidance of close to 30% growth and margins of 18% to 20%.

About Hikma

For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the North America, the MENA and Europe. For more information, please visit: www.hikma.com

Permalink

https://aetoswire.com/en/news/2112023355811

Contacts

Susan Ringdal

+44 (0)2073992760

+44 (0)7776477050

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

 

CHALFONT ST GILES, England - Thursday, 02. November 2023 AETOSWire  

New data supports the potential role of Artificial Intelligence (AI) in predicting patients’ response to immunotherapies in advance of their treatment.

AI models demonstrated 70 to 80 percent accuracy in predicting both the likelihood of efficacious response and specific immune-related toxicities.

Enables clinicians to match patients to the most effective treatment sooner, potentially avoiding unnecessary side effects and cost, and driving personalized and precise care.

 

(BUSINESS WIRE) -- GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy1, based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer (SITC) in San Diego, U.S., by GE HealthCare, Vanderbilt University Medical Center (VUMC) and the University Medicine Essen (UME), Germany. Originally developed based on a cohort of over 3,000 immunotherapy patients from VUMC and subsequently validated on a cohort of 4,000 patients from UME, the AI models predict efficacy outcomes and the likelihood of an individual patient developing an adverse reaction. This could enable precision care by unlocking the potential for clinicians to select the appropriate personalized treatment pathway sooner while potentially sparing unnecessary side effects and cost.

Immunotherapies use the immune system to recognize and attack cancer cells and can be more effective than traditional treatments, but response rates are often low and side effects can be severe.2 In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today3, selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials. After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.

To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data. The models presented at SITC use only routinely acquired data from the patient's electronic health record (EHR) as inputs, enabling versatility and scalability in their potential application.

“Immunotherapy can offer significant benefits for patients but given the current unpredictability of some reactions to treatment, it can also be associated with increased morbidity and cost. These results pave the way for the ability to better select which patients should benefit and which would be better suited to an alternative form of treatment,” said Travis Osterman, DO, MS, Associate Vice President for Research Informatics and Associate Chief Medical Information Officer for Vanderbilt University Medical Center, and Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center.

"In our joint work, we have shown that the AI models are effective across both sides of the Atlantic, paving the way for real world applications that could offer significant benefits for cancer patients treated with immunotherapies." said Jens Kleesiek, MD, PhD, Head of the Medical Machine Learning Department at the Institute for AI in Medicine and Associate Director of the West German Cancer Center of the University Medicine Essen.

“These results are a promising development in the journey towards precision care, selecting treatment pathways based on the individual patient’s likely response. We are keen to partner with pharmaceutical companies, researchers, and clinicians to optimize and apply our AI models in therapy development and in clinical practice in a longer term,” said Julia Casey, General Manager Molecular Imaging at GE HealthCare’s Pharmaceutical Diagnostics segment.

The AI models are an integral part of GE HealthCare’s immuno-oncology development portfolio which includes the development of novel PET tracers. The company recently announced the first patient scanned in a Phase I clinical trial of a first-of-its kind fluorine-18 PET radiopharmaceutical specific for CD8. Almost all immunotherapies work by activating CD8+ T cells - a subpopulation of white blood cells which fight cancer - both within and outside a tumor.

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology, and oncology, with an innovative pipeline, all aimed at enabling better-informed diagnosis and monitoring for improved therapy decision-making and clinical outcomes.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

About Vanderbilt University Medical Center

Vanderbilt University Medical Center (VUMC) is the largest comprehensive research, teaching and patient care health system in the Mid-South region of the U.S., with the highest ranked adult and children’s hospitals in the Southeast by U.S. News & World Report. Based in Nashville, Tennessee, VUMC sees more than 3.2 million patient visits per year in over 180 ambulatory locations, performs 91,000 surgical operations and discharges 79,000 inpatients from its main-campus adult, children’s, psychiatric and rehabilitation hospitals and three regional community hospitals. The Medical Center is the largest non-governmental employer of Middle Tennesseans, with nearly 40,000 staff, including more than 3,000 physicians, advanced practice nurses and scientists appointed to the Vanderbilt University faculty. For more information and the latest news follow VUMC on Facebook, LinkedIn, Twitter and in the VUMC Reporter.

About The University Medicine Essen (UME)

Including its four subsidiary hospitals, University Medicine Essen comprises a total of 32 clinics and 24 institutes. Around 10,000 experts provide their know-how for more than 70,000 inpatients and 300,000 outpatients per year. Several hundred physicians and scientists work together at the West German Cancer Center Essen, the comprehensive cancer center of the University Hospital Essen, to offer cancer patients innovative interdisciplinary treatment programs and individualized therapies. With standout categories in electronic functionalities and artificial intelligence, UME is ranked in the top 20 of Newsweek World's Best Smart Hospitals 2023.

1 Poster “Evaluation of Machine Learning Models to Predict Efficacy and Toxicity of Immune Checkpoint Inhibitors Using an External Real-World Pan-Cancer Cohort” to be presented at SITC 38th Annual meeting

2 https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief#:~:text=It%20doesn't%20work%20for,are%20about%2015%20to%2020%25. Accessed on October 31, 2023.

3 Shankar L. et al. Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. Lancet Oncology 2023; 24(3): e133-e143. doi: 10.1016/S1470-2045(22)00742-2

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20231101659257/en/

Permalink

https://www.aetoswire.com/en/news/0211202335590

Contacts

GE HealthCare Media Contact:

Mathilde Bouscaillou

+33 647 008 271

Mathilde.bouscaillou@ge.com

Vanderbilt University Medical Center Media Contact:

John Howser

615-322-4747

John.howser@vumc.org

University Medicine Essen Media Contact:

Achim Struchholz

Achim.Struchholz@uk-essen.de